JPRN-UMIN000042481Recruiting未知
Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function. - Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Saiseikai Yokohamashi Nanbu Hospital0 sites80 target enrollmentStarted: November 18, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients with severe liver dysfunction 2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 4) Patinet with diabetic ketoacidosis 5) Patient with infection 6) Patients taking steroid 7) Patients with malignant tumor currently undergoing treatment 8) Pregnant or lactating woman 9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Investigators
Similar Trials
Completed
Phase 4
Exploratory study to assess blood sugar control through the continuous use glucose monitor in patients with type 2 diabetes treated with basal insulin randomized to insulin glargine 300u / ml or glargine 100 u / ml been a 21 week single site study open with parallel armsRBR-35nvnjCPCLIN - Centro de Pesquisas Clinicas LTDA
Not yet recruiting
Phase 3
Comparison of efficacy and safety of different doses of metformin in women with gestational diabetes mellitusCTRI/2023/11/059803All India Institute of Medical Sciences New Delhi
Recruiting
Phase 4
Pilot study to evaluate glycemic control using GlucoTab in combination with continuous glucose monitoring in non-critically ill patients with type 2 diabetes at the general wardE11Type 2 diabetes mellitusDRKS00030400Medizinische Universität Graz30
Completed
Phase 4
Pilot study to evaluate glycemic control withGlucoTab using an ultra-long acting insulinanalogue in non-critically ill patients with type 2diabetes at the general wardE11Type 2 diabetes mellitusDRKS00011487niversitätsklinik für Innere Medizin, Abteilung für Endokrinologie und Diabetologie30
Active, not recruiting
Phase 1
Pilot study to evaluate glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the genaral ward - GlucoTab_DegludecDiabetes Mellitus Type 2, HyperglycaemiaEUCTR2018-002646-36-ATMedical University of Graz30